PLYMOUTH, Minn.—Trelleborg Medical Solutions, one of three business divisions for Sweden-based Trelleborg A.B., has added to its testing capabilities with a 490-sq.-ft. addition at its Tustin, Calif., facility.
The new space will allow for analytical testing to develop sustained-release and drug-elution technologies for pharmaceutical customers.
"We are equipped to support customers that need to transfer an existing test method or develop a new one," said Don Bonitati, Americas segment director, Trelleborg Medical Solutions. "Not every pharmaceutical company has the capacity or experience to perform its own product release testing.
"We recognize that each product is unique, so we've established methods that fit a product's specific characteristics, ensuring accurate and reliable results while maintaining cost-effectiveness."
Trelleborg Medical Solutions, based in Plymouth, Minn., develops polymers and solutions for OE medical, biotech and pharmaceutical customers.
"Be it early-stage development, clinical production, manufacturable scalability or market product support, our analytical team can help," Bonitati said. "We can assist with anything from study design and method development to the execution of tests that provide meaningful data to advance implantable drug delivery systems and combination devices."
The Tustin site typically conducts material characterization and takes products through to the prototype and development stages. As well, scientists there analyze active pharmaceutical ingredients—the substances responsible for the therapeutic action of the drug, excipient polymers and other materials.
